DermaPure receives Medicare coverage & reimbursement

Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces its DermaPure® dermal allograft has received notice of Local Coverage Determination (LCD) from the Medicare Administrative Contractor (Novitas) that oversees Jurisdiction J-H and Jurisdiction J-L, effective April 9, 2015. This represents a key milestone in the post-acute or outpatient care setting for the usage and reimbursement of DermaPure® for patient wound care. After receiving a Q-code in January from the Center for Medicare and Medicaid Services ("CMS"), the US Federal Government funded health programme, LCD approval from the various jurisdictions is the final step needed that enables the outpatient medical facility to obtain reimbursement for the product for qualified patients.

The J-H jurisdiction spans the states of Colorado, New Mexico, Oklahoma, Texas, Louisiana, Mississippi and Arkansas and the J-L jurisdiction spans Washington DC, Delaware, Maryland, New Jersey and Pennsylvania with total health care coverage for the two jurisdictions of 8.9 million Medicare beneficiaries. This decision will allow greater access to DermaPure® for clinicians and provide an advanced treatment option for patients suffering from chronic and acute wounds meeting medical necessity criteria.

Antony Odell, CEO of Tissue Regenix
DermaPure® has achieved outstanding clinical results in numerous acute care institutions following its introduction in June of last year.  We are delighted with the opportunity to expand our reach to help patients in the post-acute environment, including wound care centers and ambulatory surgical centers.  These facilities represent a significant usage of skin substitutes for wound care treatment.
Antony Odell, CEO of Tissue Regenix

Tissue Regenix will continue actively engaging with the other LCD jurisdiction contractors to further the benefits of DermaPure to healthcare providers and patients in other US geographies.